Trial Profile
Assess the Increased Mortality Risk With Each Year of Delayed TIS Initiation, and the Effect of TIS on Mortality Across Study Centers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Tobramycin (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 23 Nov 2021 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 29 Oct 2011 New trial record